Capricor Therapeutics (CAPR) Earnings Analysis

Capricor Therapeutics (CAPR) next reports earnings on 2026-08-11, consensus EPS -0.58 USD. Last quarter (2026-03-12) it missed with EPS -0.62 USD vs -0.51 USD est (-21.6%). It has beaten estimates in 2/5 recent quarters (40%). Trailing P/E -8.15.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CAPR next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.58 USD
Revenue estimate0.00B

CAPR earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-03-12-0.62 USD-0.51 USD-21.6%Miss
2025-11-10-0.54 USD-0.54 USD0%Beat
2025-08-11-0.57 USD-0.48 USD-18.7%Miss
2025-03-19-0.16 USD-0.31 USD+48.4%Beat
2024-11-13-0.38 USD-0.36 USD-5.6%Miss

Beat rate: 2/5 (40%) over reported quarters with consensus data.

CAPR valuation and analyst view

Trailing P/E-8.15
Trailing EPS-1.99521 USD
Price / book3.90
Dividend yield0.00%
Market cap0.88B
Analyst consensusBuy (10 buy / 0 hold / 0 sell)
Avg price target38 USD

Related research pages

Frequently asked questions

When is Capricor Therapeutics (CAPR)'s next earnings date?

Capricor Therapeutics is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.58 USD and revenue estimate of 0.00B.

Did CAPR beat earnings last quarter?

In its 2026-03-12 report, CAPR posted EPS of -0.62 USD versus a -0.51 USD estimate — a miss of 21.6%.

What is CAPR's earnings track record?

Over the last 5 reported quarters with consensus data, CAPR beat estimates 2 times (40%).

What is CAPR's current P/E ratio and EPS?

CAPR trades at a trailing P/E of -8.15 on trailing EPS of -1.9952147556788702 USD.

What do analysts rate CAPR?

Analyst consensus is "Buy" across 10 ratings (0 strong buy, 10 buy, 0 hold, 0 sell, 0 strong sell). Average 12-month price target: 38 USD.